Silexion Therapeutics (SLXN) Research & Development (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Research & Development of $1.4 million for Q1 2026, up 132.2% year-over-year from $590000.0 in Q1 2025, and down 59.41% quarter-over-quarter from $3.4 million in Q4 2025.
Silexion Therapeutics (SLXN) Research & Development (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 132.2% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $7.9 million (up 45.48% YoY), while the FY2025 annual figure was $7.1 million, up 22.79% from the prior year.
- Research & Development for Q1 2026 stood at $1.4 million, down from $3.4 million in the prior quarter.
- The five-year high for Research & Development was $3.4 million in Q4 2025, with the low at $535000.0 in Q3 2023.
- The 4-year median for Research & Development is $1.1 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 501.31% in 2024, then slumped 38.61% in 2025.
- Silexion Therapeutics' Research & Development stood at $1.3 million in 2023, then plunged by 30.71% to $871000.0 in 2024, then surged by 287.49% to $3.4 million in 2025, then slumped by 59.41% to $1.4 million in 2026.
- Business Quant data shows SLXN's Research & Development at $1.4 million in Q1 2026, $3.4 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Silexion Therapeutics | 271,023.30 | -1.96 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 3.38 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 1.02 Mn |
| Mar 31, 2025 | 590,000.00 |
| Dec 31, 2024 | 871,000.00 |
| Sep 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 766,000.00 |
| Mar 31, 2024 | 961,000.00 |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 535,000.00 |
| Jun 30, 2023 | 1.24 Mn |